For Immediate Release
Chicago, IL – September 27, 2012 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include Express Scripts Holding Company (ESRX), Walgreen (WAG), Staples Inc. (SPLS), OfficeMax Inc. (OMX) and Office Depot Inc. (ODP).
Get the most recent insight from Zacks Equity Research with the free Profit from the Pros newsletter: http://at.zacks.com/?id=5513
Here are highlights from Wednesday’s Analyst Blog:
Expansion at Express Scripts
Express Scripts Holding Company (ESRX) recently announced that it has expanded its customer base through its newly rebranded Federal Pharmacy Services unit. Express Scripts, which had so far provided services to the US Department of Defense (DoD) and the 9.7 million beneficiaries under the DoD’s TRICARE healthcare scheme, aims to serve other federal agencies through this move.
We note that the TRICARE pharmacy program is managed by the TRICARE Management Activity (:TMA) of the DoD. The program encompasses active and retired military members and their families and others eligible for DoD medical care.
Express Scripts’ decade long association with the DoD has worked very well. The partnership apart from bringing down pharmacy costs has increased beneficiary satisfaction. Express Scripts stated in its press release that the creation of the new unit will not impact this decade long association. Express Scripts merely aims to expand its pharmacy benefit management services to federal employees and their families.
Express Scripts has been constantly working to upgrade its services. Last month, the company launched an innovative online tool, virtual coaching, to facilitate better understanding among patients of the disease affecting them and the mechanism of the resultant therapy.
The visual and audible information provided by the online tool to the patients helps in improving their understanding. The new online offering targets patients suffering from serious diseases such as hepatitis C, hemophilia, multiple sclerosis apart from autoimmune deficiencies.
We have an Outperform recommendation on Express Scripts. The stock carries a Zacks #1 Rank (Strong Buy rating) in the short run. Strong second quarter 2012 results, an upbeat guidance and the favorable resolution of its long-standing dispute with retail giant Walgreen (WAG), justify our bullish stance on Express Scripts.
Staples Finds Ways to Rebound
Staples Inc. (SPLS) has been grappling with lingering economic woes and soft job market that have been impeding its growth. Consequently, this leading retailer of office products and services came up with slew of measures, which it believes will prove to be a game changer.
In a move to uplift itself, Staples now tends to focus on improving store productivity, accelerating growth in adjacent categories, reviving international operations, and streamlining cost structure. Through its cost-cutting endeavors, the company intends to save approximately $250 million annually by the end of fiscal 2015.
With the economy still struggling to find its way out of the woods, consumers and small businesses remain apprehensive about big-ticket spending such as business machines and other durables. Thus, the demand for office products is likely to remain slothful as the performance of this sector is correlated to the economy’s health.
Accordingly Staples is now concentrating more on product categories adjacent to core office supplies, such as facilities and breakroom supplies, copy and print, mobile phones and accessories, and new technology products like tablets and eReaders.
Further, with increasing consumers’ inclination toward online shopping, the companies are contemplating to enhance their e-commerce activities. Staples also felt the need of coalescing U.S. Retail and Staples.com businesses to better serve the changing preferences of consumers, as well as augmenting investment in online and mobile competences.
Given the unstable environment, we appreciate Staples’ rational approach to close underperforming locations and downsize stores. As a part of its strategy to optimize real estate portfolio, Staples hinted to shrink its store square footage by about 15% in North America, involving closure of 15 U.S. outlets, by the end of fiscal year 2015. The company plans to close 30 stores and said that 30 more are under scanner to undergo relocation or downsizing.
With the European debt crisis yet to be fixed, Staples has a dull picture to portray as it suffered a 9% decline in its comparable-store sales in the region in the last reported quarter. In order to revamp its beleaguered European operations, Staples plans to close 45 outlets and cease delivery businesses by the end of the current fiscal year.
The company also announced that John Wilson will now spearhead the European operations, in place of Rob Vale, who is retiring. As a part of its restructuring plan, Staples plans to divest European Printing Systems unit and refurbish its Australian operations.
These restructuring actions also relate to the muted second-quarter 2012 performance. Staples posted earnings of 18 cents a share that missed the Zacks Consensus Estimate of 22 cents and decreased 18% from the prior-year quarter due to lower-than-expected sales trends in North America and continuing softness in Europe and Australia.
The company witnessed a sharp fall in computer sales and sluggish trends in core categories. Total sales of $5,498.5 million declined 6% year over year, and also fell short of the Zacks Consensus Estimate of $5,721 million.
Given the disappointing results, management lowered its guidance and now expects sales for fiscal 2012 to remain flat compared with the prior year, while the bottom line is expected to increase in low single digits. Earlier, Staples had guided sales to increase in the low single digits and earnings per share to rise in the high single digits in fiscal 2012.
However, Staples did not forget its commitment toward stakeholders and is returning much of its free cash to them. The company also maintains credit ratios that are necessary for an investment-grade rating. Staples’ buyback plan includes shares worth $450 million and expects to reimburse Senior Notes of $325 million due October 2012. The company expects to return over $1 billion to shareholders during fiscal 2012.
Currently, we prefer to be on the sidelines until the efforts taken to combat the uneven economic recovery result in top and bottom lines’ growth. Consequently, we maintain our Neutral recommendation on the stock. However, Staples, which competes with OfficeMax Inc. (OMX) and Office Depot Inc. (ODP), holds Zacks #4 Rank that translates into a short-term Sell rating, and well defines the current scenario with which the company is contending.
Want more from Zacks Equity Research? Subscribe to the free Profit from the Pros newsletter: http://at.zacks.com/?id=5515.
About Zacks Equity Research
Zacks Equity Research provides the best of quantitative and qualitative analysis to help investors know what stocks to buy and which to sell for the long-term.
Continuous coverage is provided for a universe of 1,150 publicly traded stocks. Our analysts are organized by industry which gives them keen insights to developments that affect company profits and stock performance. Recommendations and target prices are six-month time horizons.
Zacks "Profit from the Pros" e-mail newsletter provides highlights of the latest analysis from Zacks Equity Research. Subscribe to this free newsletter today: http://at.zacks.com/?id=5517
Zacks.com is a property of Zacks Investment Research, Inc., which was formed in 1978 by Leon Zacks. As a PhD from MIT Len knew he could find patterns in stock market data that would lead to superior investment results. Amongst his many accomplishments was the formation of his proprietary stock picking system; the Zacks Rank, which continues to outperform the market by nearly a 3 to 1 margin. The best way to unlock the profitable stock recommendations and market insights of Zacks Investment Research is through our free daily email newsletter; Profit from the Pros. In short, it's your steady flow of Profitable ideas GUARANTEED to be worth your time! Register for your free subscription to Profit from the Pros at http://at.zacks.com/?id=5518.
Visit http://www.zacks.com/performance for information about the performance numbers displayed in this press release.
Follow us on Twitter: http://twitter.com/zacksresearch
Join us on Facebook: http://www.facebook.com/home.php#/pages/Zacks-Investment-Research/57553657748?ref=ts
Disclaimer: Past performance does not guarantee future results. Investors should always research companies and securities before making any investments. Nothing herein should be construed as an offer or solicitation to buy or sell any security.
Zacks Investment Research
800-767-3771 ext. 9339
More From Zacks.com
- Investment & Company Information
- Express Scripts